2D cell line
Fast, simple
Organoids: Shaping the Future of Precision Medicine
From self-organizing models to drug testing, regulatory science and regenerative medicine
01 | Introduction
What is organoid?
An organoid is a three-dimensional structure generated from pluripotent or tissue-resident stem cells that self-organize and reproduces selected structural, cellular and functional features of its tissue of origin.
It is not a miniature, fully functioning organ. Its relevance depends on the biological question and the assay's context of use.
Organoids add three-dimensional, tissue-specific biology between simplified cell assays and whole-organism studies.
3D
Self-organizing architecture and cell–cell interaction
Human
Human or patient-derived biological context
Scalable
Expandable models for repeated perturbation and screening
Fifteen years ago, organoids were a developmental-biology curiosity. Today they sit at the intersection of drug discovery, precision oncology, and a regulatory revolution that is rewriting how new medicines reach patients.
~90%
Clinical-trial failure rate that organoid-based screening aims to reduce
~19%
CAGR projected for the human organoids market through 2034
~2.5 yrs
Idea-to-clinic timeline for a Roche antibody developed using organoid data alone
Where it sits in the model spectrum
Primary cell
Human tissue, limited expansion
Organoid
3D tissue context
Engineered organoid
Added flow, stroma, immunity or vasculature
Animal / patient
Systemic biology / clinical outcome
Bottom line
Organoids occupy a middle ground: more human-relevant than reductionist assays, more scalable than whole-organism models, but not a complete model of human biology.
02 | Chronological evolution
A century of self-organization research has become an organ-by-organ technology platform
The modern field accelerated after pluripotent-stem-cell advances and the 2009 intestinal-organoid breakthrough
Chronological evolution of organoid technology: key scientific, regulatory and commercial milestones, 1907–2026.
Transition
The same history also explains why formation strategy matters: organoids inherit different strengths and limitations from the cells and culture cues used to build them.
03 | Applications across disease areas
Organoids allow scientists to study human-like models for disease research and therapeutic development
Organoids are most valuable when traditional models cannot accurately mimic human biology
| Disease domain | Representative organoid examples | What the model can reveal |
|---|---|---|
| Genetic developmental | Microcephaly; DNAJC6-associated Parkinson's disease; APOE4 Alzheimer's disease; CRX-Leber congenital amaurosis; polycystic kidney disease | Helps understand how genetic mutations affect human organ development, identify disease mechanisms, and evaluate potential gene correction or targeted therapies |
| Infectious disease | Zika and SARS-CoV-2 brain models; SARS-CoV-2 nasal and distal-lung models; Pseudomonas airway models; intestinal host–microbe systems | Shows how microorganisms infect human tissues, spread between cells, damage organs, and trigger the body's immune response |
| Inflammatory & autoimmune | Inflammatory bowel disease; Hashimoto's thyroiditis; Graves' hyperthyroidism | Reveals how immune cells interact with tissues, why inflammation occurs, how patients differ in disease biology, and which treatments may work best |
| Metabolic & toxic injury | Diabetic vasculopathy; alcohol-related liver disease; drug-induced liver injury; kidney nephrotoxicity | Demonstrates how metabolic disorders or drugs damage specific organs, identifies early signs of toxicity, and compares diseased tissue with healthy tissue |
| Cardiovascular | Myocardial infarction and hypoplastic left-heart syndrome | Helps study changes in heart structure and function, understand disease progression, and evaluate how the heart responds to potential therapies |
| Cancer | Glioblastoma, retinoblastoma, lung, colorectal, gastric, pancreatic, gallbladder and ovarian cancers | Recreates patient tumors to study tumor biology, genetic diversity, drug sensitivity and resistance, enabling personalized treatment selection and biomarker discovery |
“One antibody went from an idea to human patients in two and a half years, based on organoid testing alone — with no animal or cell lines involved.”— Hans Clevers, Roche Institute of Human Biology
Key capabilities demonstrated by organoids
- Treatment-response modelling: Patient-derived organoids from metastatic gastrointestinal cancers reproduced clinically relevant treatment response.
- High-throughput screening: One study tested 240 FDA-approved or clinically developed protein-kinase inhibitors in patient-derived ovarian-cancer organoids.
- Therapeutic window: Gallbladder-cancer organoids identified CUDC-907 activity with minimal toxicity in organoids derived from normal gallbladder tissue.
Caution
Recapitulating one disease feature is not equivalent to reproducing the complete disease. Model validity must be linked to the specific mechanism or decision being tested.
04 | Clinical evidence | Drug testing
Clinical investigation is concentrated on treatment-response testing, especially oncology
Organoid-guided trials are expanding across cancers, demonstrating growing confidence in their role in personalized medicine and clinical decision-making
110
Registered trials identified using “organoids”
9
Brain tumour & breast cancer trials
18
Gastrointestinal trials
8
Advanced solid tumours
41
Other oncology trials
Representative Clinical Trials Using Organoid-Guided Drug Testing
| Disease | Objectives | Phase | Status | Start | Trial ID |
|---|---|---|---|---|---|
| Gastric Cancer | Generate patient-derived gastric organoids to test the effects of pyrvinium | Phase 2 | Recruiting | Dec-2025 | NCT06590454 |
| Wilms Tumor | Develop organoid models to study Wilms tumor and compare responses to chemotherapeutic agents | Phase 2 | Recruiting | Aug-2021 | NCT04968990 |
| Colorectal Cancer | Individualized treatment using pharmacogenomics and patient-derived organoids in metastatic colorectal cancer | Phase 2 | Recruiting | Sep-2022 | NCT05725200 |
| Thyroid Carcinoma | Organoid-guided precision medicine in locally advanced thyroid cancer | Phase 2 | Recruiting | Jun-2021 | NCT06482086 |
| Pancreatic Cancer | Adaptive organoid-based precision therapy study in pancreatic cancer | Phase 2 | Recruiting | Jul-2022 | NCT06813079 |
| Breast Cancer | Patient-derived organoid-guided personalized therapy vs physician's choice in relapsed/refractory breast cancer | Phase 3 | Recruiting | Jan-2024 | NCT06266652 |
| Small Cell Lung CancerSCLC | Organoid-guided vs topotecan therapy in relapsed extensive-stage SCLC | Phase 3 | Not yet recruiting | Jul-2025 | NCT07106628 |
Trial identifiers link to the corresponding ClinicalTrials.gov record.
Key insights
- Most trials had started within the preceding five years and were predominantly sponsored by institutions or individuals in China and the United States.
- Oncology accounted for most organoid-related clinical studies (~69%): multiple/advanced solid tumors, lung cancer, gastric and esophageal cancers, ovarian cancer, sarcoma, biliary tract/gallbladder cancers, liver cancer, bladder cancer and prostate cancer, among others.
- While oncology remains the dominant application, non-oncology research is expanding (~31%) into diverse therapeutic areas, particularly gastrointestinal, neurological, metabolic and rare genetic diseases.
Furthermore, recent advances in regenerative medicine have moved organoid transplantation from experimental models toward clinical application.
2021
Adult stem cell-derived bile duct organoids repaired biliary epithelium and retained plasticity following transplantation into the human biliary tree
2022
Autologous intestinal organoids derived from healthy mucosal stem cells of patients with ulcerative colitis by a Japanese research team
2023
Allogeneic iPSC-derived retinal organoid sheets show increased retinal thickness with no serious adverse events in two patients with advanced retinitis pigmentosa
These milestones illustrate the evolution of organoids from laboratory models to therapeutic products, marking an important step toward regenerative medicine and organ replacement therapies.
05 | Regulatory shift
U.S. FDA policy is moving from animal-default evidence towards validated, fit-for-purpose new approach methodologies (NAMs)
The direction is clear; the acceptable evidence package remains product-, endpoint- and context-specific.
- Dec 2022
- FDA Modernization Act 2.0 amended the statutory framework to recognize non-animal tests among nonclinical options, making animal studies no longer the only legally recognized route.
- Apr 2025
- FDA roadmap launched with an initial focus on monoclonal antibodies and encouraged organoids, organ-on-chip, in-silico models and other NAM data, providing sponsors with a staged pathway to reduce, refine or replace selected animal studies.
- Dec 2025
- Draft mAb guidance described when toxicology studies may be unnecessary, shortened or supported by weight-of-evidence risk assessment, potentially reducing selected non-human primate testing.
- Mar–Apr 2026
- FDA issued draft NAM validation principles and reported first-year implementation progress, emphasizing context of use, human relevance, technical characterization and fitness for purpose as key criteria for regulatory acceptance.
Four validation principles in FDA's 2026 draft guidance
01
Context of use
Define the specific purpose and decision the model is intended to support.
02
Human biological relevance
Demonstrate that the model accurately reflects key aspects of human biology and disease.
03
Technical characterization
Establish the model's reproducibility and performance using standardized methods.
04
Fit for purpose
Provide evidence that the model is suitable for its intended regulatory or research application.
What changed — and what did not
What changed
Policy signal: NAM evidence is actively encouraged, and formal validation expectations are emerging.
Development option: Some animal studies may be reduced, refined or replaced where equivalent or better evidence exists.
Strategic priority: Assay qualification and early regulatory dialogue become valuable capabilities.
What did not
No universal waiver: Organoids do not automatically replace systemic or long-duration evidence.
No platform-wide acceptance: Validation is tied to a specific endpoint and context of use.
Clinical trials remain: Human efficacy and safety evaluation are not removed by an organoid-enabled preclinical package.
Regulatory takeaway
The relevant question is not “Does FDA accept organoids?” It is “Can this assay reliably answer this regulatory question in this product context?”
06 | Industry role
Leading pharma companies are expanding organoid capabilities to accelerate R&D and precision medicine
Industry leaders are investing in organoid capabilities to improve translational predictability, enable precision medicine and accelerate drug development.
| Company | Strategy | Example |
|---|---|---|
| Roche / Genentech | In-house discovery institute, founder-led | The Roche Institute of Human Biology (IHB), founded around organoid pioneer Hans Clevers, took a novel antibody from concept to first-in-human trials in 2.5 years using organoid data alone, without conventional animal or 2D cell-line testing. |
| Merck KGaAMilliporeSigma | Platform built via acquisition | Acquired HUB Organoids (deal closed Dec 2024, ~€104M/$120M) for its gastrointestinal, lung and pancreatic organoid biobanks, then partnered with Promega (Oct 2025) to build real-time reporter assays inside organoid cultures. |
| GSK | Acquisition + first-of-kind clinical trial | Acquired CELLphenomics (2024) for its patient-derived organoid platform; now running what it describes as the first trial combining organoids, AI and imaging as “digital biological twins,” growing organoids from ~200 NHS non-small-cell lung cancer patients with King's College London. |
| AstraZeneca | Academic-consortium biobank building | Built new lung-cancer organoid models with Royal Papworth Hospital, the Wellcome Sanger Institute and the Human Cancer Models Initiative to cover mutation subtypes no existing preclinical model captured. |
| Boehringer Ingelheim | In-house global oncology hub | BI's Vienna cancer hub has used organoids since roughly 2019; it is now converting its patient-derived xenograft (PDX) mouse-model bank into organoid panels with Charles River, aiming for PDX-level tumor diversity without the animal. |
| Vertex Pharmaceuticals | Regulatory-grade biomarker in rare disease | Uses patient rectal/intestinal organoid “theratyping” to test CFTR modulators against mutations too rare for clinical trials; this organoid-derived functional data has supported regulatory label expansions of its CFTR modulators to thousands of rare-genotype cystic fibrosis patients. |
Strategic implications
- Large pharmaceutical companies are embedding organoids into core R&D strategies through diverse approaches, including internal platform development (Roche, Boehringer Ingelheim), strategic acquisitions (Merck KGaA, GSK) and academic collaborations (AstraZeneca), indicating that organoids are becoming a strategic capability rather than a niche research tool.
- Industry investment is shifting toward scalable, human-relevant platforms that can reduce reliance on traditional animal models. Companies are integrating organoids with AI, imaging, biobanks and functional assays to generate clinically predictive data and accelerate drug development.
07 | Limitations
No single experimental model wins across all dimensions; model selection is a portfolio decision
Organoids trade whole-body completeness for human relevance, manipulability and scale.
What still limits routine adoption and how the field is responding
| Constraint | Why it matters | Development response |
|---|---|---|
| Incomplete microenvironment | Many models lack stroma, immune cells, endothelium, nerves or organ–organ interaction. | Co-culture, vascularization, microfluidics and multi-organoid systems |
| Immaturity | PSC-derived models often resemble fetal rather than adult tissue. | Longer culture, bioreactors, transplantation and maturation cues |
| Reproducibility | Patient, protocol, cytokine, matrix and cell-composition variation affects results. | Reference standards, automation, defined media and release criteria |
| Matrix dependence | Matrigel and related animal-derived products vary by batch and are poorly suited to transplantation. | Defined synthetic, biomimetic and decellularized-tissue hydrogels |
| Throughput & economics | Complex culture, imaging and analytics can constrain scale and turnaround. | Miniaturization, robotics, high-content imaging and AI |
| Clinical safety & ethics | Tumorigenicity, off-target cells, immune risk and brain-organoid ethics require governance. | GMP-compatible processes, long-term testing, transparent oversight and context-specific ethics |
Balanced view
Organoids complement rather than universally replace cell lines, animals or clinical evidence. Their value is highest when the model's limitations are explicit and matched to the decision.
08 | Future prospects & key takeaways
The next frontier is evidence integration: biology, engineering, data and regulation
Success will be measured by reproducibility and decision impact, not by anatomical resemblance alone.
Six developments most likely to determine impact
- Standardized, defined culture systems
- Cross-laboratory comparability, scalable quality control and transplant-compatible production
- Vascular, immune and stromal integration
- More mature disease biology, immunotherapy testing and tissue repair
- Multi-organoid chips
- Organ–organ interactions, distribution and multi-organ toxicity within controllable systems
- AI with multi-omics qualification
- Objective phenotypes, model benchmarking and interpretable response signatures
- Clinically linked living biobanks
- Prospective validation, patient stratification and durable learning systems
- Regenerative manufacturing
- Safe expansion, delivery, engraftment and long-term function under GMP-compatible workflows
Key takeaways
- Organoids have progressed from self-organization experiments to a multi-tissue translation platform.
- Formation strategy determines maturity, cellular complexity and patient relevance; model selection must follow the question.
- Drug testing and precision oncology lead clinical activity, but prospective outcome evidence remains the decisive gap.
- Human transplantation is real but early — most evidence still comes from animal recipients.
- The regulatory opening rewards validated, context-specific NAMs, not blanket replacement claims.
- Competitive advantages will combine biological assets, reproducible assays, linked data, operational scale and regulatory credibility.
Organoids: Powerful Through Precision,
Not Perfection
References
- Yao Q, Cheng S, Pan Q, et al. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine. MedComm. 2024;5:e735. doi:10.1002/mco2.735. doi.org
- National Cancer Institute. Definition of organoid. NCI Dictionary of Cancer Terms. cancer.gov
- Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–265. nature.com
- Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920–926. science.org
- Hirami Y, Mandai M, Sugita S, et al. Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa. Cell Stem Cell. 2023;30:1585–1596.e6. cell.com
- Sampaziotis F, Muraro D, Tysoe OC, et al. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. Science. 2021;371:839–846. science.org
- U.S. FDA. FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs. 10 April 2025. fda.gov
- U.S. FDA. Roadmap to Reducing Animal Testing in Preclinical Safety Studies. April 2025. fda.gov
- U.S. FDA. Monoclonal Antibodies: Streamlined Nonclinical Safety Studies. Draft Guidance. December 2025. fda.gov
- U.S. FDA. General Considerations for the Use of New Approach Methodologies in Drug Development. Draft Guidance. March 2026. fda.gov
- U.S. FDA. FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development. 20 April 2026. fda.gov
- National Toxicology Program / NICEATM. Regulatory Applications of 3Rs: FDA Modernization Act 2.0. Accessed July 2026. ntp.niehs.nih.gov
- Merck KGaA. Acquisition of HUB Organoids Holding B.V. 6 January 2025. merckgroup.com
- Roche. Accelerating drug discovery with organoids. 27 November 2025. roche.com
- GSK. Digital biological twins and organoids might sound like sci-fi. 10 June 2025. gsk.com
- Crown Bioscience. Patient-Derived Organoids for Oncology Drug Development. Accessed July 2026. crownbio.com
- Emulate. Organ-Chips for Research & Development. Accessed July 2026. emulatebio.com
- AstraZeneca. Using Cancer Organoids to Discover New Therapeutic Targets. November 2022. astrazeneca.com
- Boehringer Ingelheim. Organoids in Drug Development: Evolving and Expanding. April 2024. boehringer-ingelheim.com
- Conti J, Sorio C, Melotti P. Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis. Children (Basel). 2022 Dec 20;10(1):4. mdpi.com
Prepared by PharmSight Research & Analytics for informational purposes only.